{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:17:34Z","timestamp":1792466254780,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T00:00:00Z","timestamp":1557100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T00:00:00Z","timestamp":1557100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intensive Care Med"],"published-print":{"date-parts":[[2019,6,1]]},"DOI":"10.1007\/s00134-019-05620-2","type":"journal-article","created":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T12:33:55Z","timestamp":1557146035000},"page":"844-855","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":151,"title":["Vasopressin in septic shock: an individual patient data meta-analysis of randomised controlled trials"],"prefix":"10.1007","volume":"45","author":[{"given":"Myura","family":"Nagendran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith R.","family":"Walley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Brett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin D.","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludhmila","family":"Hajjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexina J.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Ashby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony C.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,6]]},"reference":[{"key":"5620_CR1","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMra1208943","volume":"369","author":"JL Vincent","year":"2013","unstructured":"Vincent JL, De Backer D (2013) Circulatory shock. N Engl J Med 369:1726\u20131734","journal-title":"N Engl J Med"},{"key":"5620_CR2","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1056\/NEJMoa0907118","volume":"362","author":"D De Backer","year":"2010","unstructured":"De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, Brasseur A, Defrance P, Gottignies P, Vincent JL (2010) Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 362:779\u2013789","journal-title":"N Engl J Med"},{"key":"5620_CR3","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1007\/s00134-015-3849-3","volume":"41","author":"DJ O\u2019Callaghan","year":"2015","unstructured":"O\u2019Callaghan DJ, Gordon AC (2015) What\u2019s new in vasopressin? Intensive Care Med 41:2177\u20132179","journal-title":"Intensive Care Med"},{"key":"5620_CR4","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1161\/01.CIR.95.5.1122","volume":"95","author":"DW Landry","year":"1997","unstructured":"Landry DW, Levin HR, Gallant EM, Ashton RC Jr, Seo S, D\u2019Alessandro D, Oz MC, Oliver JA (1997) Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 95:1122\u20131125","journal-title":"Circulation"},{"key":"5620_CR5","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s00134-018-5242-5","volume":"44","author":"D Annane","year":"2018","unstructured":"Annane D, Ouanes-Besbes L, de Backer D, Du B, Gordon AC, Hernandez G, Olsen KM, Osborn TM, Peake S, Russell JA, Cavazzoni SZ (2018) A global perspective on vasoactive agents in shock. Intensive Care Med 44:833\u2013846","journal-title":"Intensive Care Med"},{"key":"5620_CR6","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa067373","volume":"358","author":"JA Russell","year":"2008","unstructured":"Russell JA, Walley KR, Singer J, Gordon AC, Hebert PC, Cooper DJ, Holmes CL, Mehta S, Granton JT, Storms MM, Cook DJ, Presneill JJ, Ayers D (2008) Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 358:877\u2013887","journal-title":"N Engl J Med"},{"key":"5620_CR7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00134-009-1687-x","volume":"36","author":"AC Gordon","year":"2010","unstructured":"Gordon AC, Russell JA, Walley KR, Singer J, Ayers D, Storms MM, Holmes CL, Hebert PC, Cooper DJ, Mehta S, Granton JT, Cook DJ, Presneill JJ (2010) The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Med 36:83\u201391","journal-title":"Intensive Care Med"},{"key":"5620_CR8","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1007\/s00134-006-0378-0","volume":"32","author":"F Lauzier","year":"2006","unstructured":"Lauzier F, Levy B, Lamarre P, Lesur O (2006) Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. Intensive Care Med 32:1782\u20131789","journal-title":"Intensive Care Med"},{"key":"5620_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00134-009-1630-1","volume":"36","author":"C Torgersen","year":"2010","unstructured":"Torgersen C, Dunser MW, Wenzel V, Jochberger S, Mayr V, Schmittinger CA, Lorenz I, Schmid S, Westphal M, Grander W, Luckner G (2010) Comparing two different arginine vasopressin doses in advanced vasodilatory shock: a randomized, controlled, open-label trial. Intensive Care Med 36:57\u201365","journal-title":"Intensive Care Med"},{"key":"5620_CR10","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1097\/CCM.0000000000000212","volume":"42","author":"AC Gordon","year":"2014","unstructured":"Gordon AC, Mason AJ, Perkins GD, Stotz M, Terblanche M, Ashby D, Brett SJ (2014) The interaction of vasopressin and corticosteroids in septic shock: a pilot randomized controlled trial. Crit Care Med 42:1325\u20131333","journal-title":"Crit Care Med"},{"key":"5620_CR11","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1097\/CCM.0b013e3181961ace","volume":"37","author":"JA Russell","year":"2009","unstructured":"Russell JA, Walley KR, Gordon AC, Cooper DJ, Hebert PC, Singer J, Holmes CL, Mehta S, Granton JT, Storms MM, Cook DJ, Presneill JJ (2009) Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Crit Care Med 37:811\u2013818","journal-title":"Crit Care Med"},{"key":"5620_CR12","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1001\/jama.2016.10485","volume":"316","author":"AC Gordon","year":"2016","unstructured":"Gordon AC, Mason AJ, Thirunavukkarasu N, Perkins GD, Cecconi M, Cepkova M, Pogson DG, Aya HD, Anjum A, Frazier GJ, Santhakumaran S, Ashby D, Brett SJ (2016) Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA 316:509\u2013518","journal-title":"JAMA"},{"key":"5620_CR13","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s00134-017-4683-6","volume":"43","author":"A Rhodes","year":"2017","unstructured":"Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerg B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinghan GJ, Bernard GR, Chiche JD, Coopersmith C, De Backer DP, French CJ, Fujishima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM, Koh Y, Lisboa TC, Machado FR, Marini JJ, Marshall JC, Mazuski JE, McIntyre LA, McLean AS, Mehta S, Moreno RP, Myburgh J, Navalesi P, Nishida O, Osborn TM, Perner A, Plunkett CM, Ranieri M, Schorr CA, Seckel MA, Seymour CW, Shieh L, Shukri KA, Simpson SQ, Singer M, Thompson BT, Townsend SR, Van der Poll T, Vincent JL, Wiersinga WJ, Zimmerman JL, Dellinger RP (2017) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 43:304\u2013377","journal-title":"Intensive Care Med"},{"key":"5620_CR14","doi-asserted-by":"publisher","first-page":"c221","DOI":"10.1136\/bmj.c221","volume":"340","author":"RD Riley","year":"2010","unstructured":"Riley RD, Lambert PC, Abo-Zaid G (2010) Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ 340:c221","journal-title":"BMJ"},{"key":"5620_CR15","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.jclinepi.2010.11.016","volume":"64","author":"DJ Fisher","year":"2011","unstructured":"Fisher DJ, Copas AJ, Tierney JF, Parmar MK (2011) A critical review of methods for the assessment of patient-level interactions in individual participant data meta-analysis of randomized trials, and guidance for practitioners. J Clin Epidemiol 64:949\u2013967","journal-title":"J Clin Epidemiol"},{"key":"5620_CR16","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1001\/jama.2015.3656","volume":"313","author":"LA Stewart","year":"2015","unstructured":"Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF (2015) Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD statement. JAMA 313:1657\u20131665","journal-title":"JAMA"},{"key":"5620_CR17","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA (2011) The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928","journal-title":"BMJ"},{"key":"5620_CR18","unstructured":"Higgins JPT, Green S (eds) (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration. Available from http:\/\/www.handbook.cochrane.org"},{"key":"5620_CR19","doi-asserted-by":"publisher","first-page":"R31","DOI":"10.1186\/cc5713","volume":"11","author":"RL Mehta","year":"2007","unstructured":"Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A (2007) Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 11:R31","journal-title":"Crit Care"},{"key":"5620_CR20","doi-asserted-by":"publisher","first-page":"R204","DOI":"10.1186\/cc2872","volume":"8","author":"R Bellomo","year":"2004","unstructured":"Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P (2004) Acute renal failure\u2014definition, outcome measures, animal models, fluid therapy and information technology needs: the second international consensus conference of the acute dialysis quality initiative (ADQI) group. Crit Care 8:R204\u2013R212","journal-title":"Crit Care"},{"key":"5620_CR21","doi-asserted-by":"publisher","first-page":"e46042","DOI":"10.1371\/journal.pone.0046042","volume":"7","author":"GB Stewart","year":"2012","unstructured":"Stewart GB, Altman DG, Askie LM, Duley L, Simmonds MC, Stewart LA (2012) Statistical analysis of individual participant data meta-analyses: a comparison of methods and recommendations for practice. PLoS One 7:e46042","journal-title":"PLoS One"},{"key":"5620_CR22","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1097\/01.CCM.0000127264.54807.B7","volume":"32","author":"MW Dunser","year":"2004","unstructured":"Dunser MW, Hasibeder WR, Wenzel V, Schwarz S, Ulmer H, Knotzer H, Pajk W, Friesenecker BE, Mayr AJ (2004) Endocrinologic response to vasopressin infusion in advanced vasodilatory shock. Crit Care Med 32:1266\u20131271","journal-title":"Crit Care Med"},{"key":"5620_CR23","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1097\/00000542-200203000-00011","volume":"96","author":"BM Patel","year":"2002","unstructured":"Patel BM, Chittock DR, Russell JA, Walley KR (2002) Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 96:576\u2013582","journal-title":"Anesthesiology"},{"key":"5620_CR24","doi-asserted-by":"publisher","first-page":"P168","DOI":"10.1186\/s13054-017-1753-7","volume":"21","author":"C Capoletto","year":"2017","unstructured":"Capoletto C, Almeida J, Ferreira G, Fukushima J, Nakamura R, Risk S, Osawa E, Park C, Oliveira G, Galas F, Franco R, Hajjar L (2017) Vasopressin versus norepinephrine for the management of septic shock in cancer patients (vancs ii). Crit Care 21:P168","journal-title":"Crit Care"},{"key":"5620_CR25","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1161\/01.CIR.0000066692.71008.BB","volume":"107","author":"MW Dunser","year":"2003","unstructured":"Dunser MW, Mayr AJ, Ulmer H, Knotzer H, Sumann G, Pajk W, Friesenecker B, Hasibeder WR (2003) Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 107:2313\u20132319","journal-title":"Circulation"},{"key":"5620_CR26","doi-asserted-by":"publisher","first-page":"578","DOI":"10.4103\/ijccm.IJCCM_258_17","volume":"21","author":"E Barzegar","year":"2017","unstructured":"Barzegar E, Nouri M, Mousavi S, Ahmadi A, Mojtahedzadeh M (2017) Vasopressin in septic shock; assessment of sepsis biomarkers: a randomized, controlled trial. Indian J Crit Care Med 21:578\u2013584","journal-title":"Indian J Crit Care Med"},{"key":"5620_CR27","first-page":"355","volume":"24","author":"TM Elmenesy","year":"2008","unstructured":"Elmenesy TM, Nassar Y (2008) A randomized double-blind comparative study between short-term norepinephrine and vasopressin infusion in septic shock. Egypt J Anaesth 24:355\u2013362","journal-title":"Egypt J Anaesth"},{"key":"5620_CR28","doi-asserted-by":"publisher","first-page":"R130","DOI":"10.1186\/cc7990","volume":"13","author":"A Morelli","year":"2009","unstructured":"Morelli A, Ertmer C, Rehberg S, Lange M, Orecchioni A, Cecchini V, Bachetoni A, D\u2019Alessandro M, Van Aken H, Pietropaoli P, Westphal M (2009) Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Crit Care 13:R130","journal-title":"Crit Care"},{"key":"5620_CR29","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1186\/cc13348","volume":"18","author":"S Oliveira","year":"2014","unstructured":"Oliveira S, Dessa F, Rocha C, Oliveira F (2014) Early vasopressin application in shock study. Crit Care 18:S56","journal-title":"Crit Care"},{"key":"5620_CR30","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC (2016) The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 315:801\u2013810","journal-title":"JAMA"},{"key":"5620_CR31","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1001\/jama.2018.4528","volume":"319","author":"WF McIntyre","year":"2018","unstructured":"McIntyre WF, Um KJ, Alhazzani W, Lengyel AP, Hajjar L, Gordon AC, Lamontagne F, Healey JS, Whitlock RP, Belley-Cote EP (2018) Association of vasopressin plus catecholamine vasopressors vs catecholamines alone with atrial fibrillation in patients with distributive shock: a systematic review and meta-analysis. JAMA 319:1889\u20131900","journal-title":"JAMA"},{"key":"5620_CR32","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1097\/CCM.0000000000003471","volume":"47","author":"WL Nedel","year":"2018","unstructured":"Nedel WL, Rech TH, Ribeiro RA, Pellegrini JAS, Moraes RB (2018) Renal outcomes of vasopressin and its analogs in distributive shock: a systematic review and meta-analysis of randomized trials. Crit Care Med 47:e44\u2013e51","journal-title":"Crit Care Med"},{"key":"5620_CR33","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00134-018-5134-8","volume":"44","author":"HJ de Grooth","year":"2018","unstructured":"de Grooth HJ, Postema J, Loer SA, Parienti JJ, Oudemans-van Straaten HM, Girbes AR (2018) Unexplained mortality differences between septic shock trials: a systematic analysis of population characteristics and control-group mortality rates. Intensive Care Med 44:311\u2013322","journal-title":"Intensive Care Med"},{"key":"5620_CR34","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1097\/CCM.0000000000002323","volume":"45","author":"JA Russell","year":"2017","unstructured":"Russell JA, Lee T, Singer J, Boyd JH, Walley KR (2017) The septic shock 3.0 definition and trials: a vasopressin and septic shock trial experience. Am J Respir Crit Care Med 45:940\u2013948","journal-title":"Am J Respir Crit Care Med"},{"key":"5620_CR35","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1164\/rccm.201807-1346OC","volume":"199","author":"PK Bhatraju","year":"2018","unstructured":"Bhatraju PK, Zelnick LR, Herting J, Katz R, Mikacenic C, Kosamo S, Morrell ED, Robinson-Cohen C, Calfee CS, Christie JD, Liu KD, Matthay MA, Hahn WO, Dmyterko V, Slivinski NSJ, Russell JA, Walley KR, Christiani DC, Liles WC, Himmelfarb J, Wurfel MM (2018) Identification of acute kidney injury sub-phenotypes with differing molecular signatures and response to vasopressin therapy. Am J Respir Crit Care Med 199:863\u2013872","journal-title":"Am J Respir Crit Care Med"},{"key":"5620_CR36","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1164\/rccm.201807-1419OC","volume":"199","author":"DB Antcliffe","year":"2018","unstructured":"Antcliffe DB, Burnham KL, Al-Beidh F, Santhakumaran S, Brett SJ, Hinds CJ, Ashby D, Knight JC (2018) Transcriptomic signatures in sepsis and a differential response to steroids: from the VANISH randomized trial. Am J Respir Crit Care Med 199:980\u2013986","journal-title":"Am J Respir Crit Care Med"},{"key":"5620_CR37","doi-asserted-by":"publisher","first-page":"R46","DOI":"10.1186\/cc8933","volume":"14","author":"N Srisawat","year":"2010","unstructured":"Srisawat N, Lawsin L, Uchino S, Bellomo R, Kellum JA (2010) Cost of acute renal replacement therapy in the intensive care unit: results from the beginning and ending supportive therapy for the kidney (BEST Kidney) study. Crit Care 14:R46","journal-title":"Crit Care"},{"key":"5620_CR38","unstructured":"Farkas J (2016) Pulmcrit\u2014renoresuscitation, vasopressin, vepinephrine, and VANISH. Pulmcrit. http:\/\/emcrit.org\/pulmcrit\/vanish-renoresuscitation-vasopressin-vepinephrine\/. Accessed 27 Jan 2019"},{"key":"5620_CR39","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1164\/rccm.201311-2097OC","volume":"189","author":"A Linder","year":"2014","unstructured":"Linder A, Fjell C, Levin A, Walley KR, Russell JA, Boyd JH (2014) Small acute increases in serum creatinine are associated with decreased long-term survival in the critically ill. Am J Respir Crit Care Med 189:1075\u20131081","journal-title":"Am J Respir Crit Care Med"},{"key":"5620_CR40","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.chest.2016.07.010","volume":"151","author":"SS Kadri","year":"2017","unstructured":"Kadri SS, Rhee C, Strich JR, Morales MK, Hohmann S, Menchaca J, Suffredini AF, Danner RL, Klompas M (2017) Estimating 10-year trends in septic shock incidence and mortality in United States academic medical centers using clinical data. Chest 151:278\u2013285","journal-title":"Chest"},{"key":"5620_CR41","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1056\/NEJMoa1701380","volume":"376","author":"KM Rowan","year":"2017","unstructured":"Rowan KM, Angus DC, Bailey M, Barnato AE, Bellomo R, Canter RR, Coats TJ, Delaney A, Gimbel E, Grieve RD, Harrison DA, Higgins AM, Howe B, Huang DT, Kellum JA, Mouncey PR, Music E, Peake SL, Pike F, Reade MC, Sadique MZ, Singer M, Yealy DM (2017) Early, goal-directed therapy for septic shock\u2014a patient-level meta-analysis. N Engl J Med 376:2223\u20132234","journal-title":"N Engl J Med"}],"container-title":["Intensive Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-019-05620-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00134-019-05620-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-019-05620-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T01:35:08Z","timestamp":1744162508000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00134-019-05620-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,6]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6,1]]}},"alternative-id":["5620"],"URL":"https:\/\/doi.org\/10.1007\/s00134-019-05620-2","relation":{},"ISSN":["0342-4642","1432-1238"],"issn-type":[{"value":"0342-4642","type":"print"},{"value":"1432-1238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,6]]},"assertion":[{"value":"7 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"LH reports that outside of this work she has received speaker fees from Amomed Pharma. ACG reports that outside of this work he has received speaker fees from Orion Corporation Orion Pharma and Amomed Pharma. ACG has consulted for Ferring Pharmaceuticals, Tenax Therapeutics, Baxter Healthcare, Bristol-Myers Squibb and GSK and received grant support from Orion Corporation Orion Pharma, Tenax Therapeutics and HCA International with funds paid to his institution. JAR reports patents owned by the University of British Columbia (UBC) that are related to the use of PCSK9 inhibitor(s) in sepsis and related to the use of vasopressin in septic shock. JAR is an inventor on these patents. JAR was a founder, Director and shareholder in Cyon Therapeutics Inc. JAR is a shareholder in Molecular You Corp. JAR reports receiving consulting fees in the last 3\u00a0years from: Asahi Kesai Pharmaceuticals of America (AKPA) (developing recombinant thrombomodulin in sepsis), SIB Therapeutics LLC (developing a sepsis drug), Ferring Pharmaceuticals (manufactures vasopressin and developing selepressin). JAR is no longer actively consulting for the following: La Jolla Pharmaceuticals (developing angiotensin II; JAR chaired the DSMB of a trial of angiotensin II from 2015 to 2017), Cubist Pharmaceuticals (now owned by Merck; formerly was Trius Pharmaceuticals; developing antibiotics), Grifols (sells albumin), CytoVale Inc. (developing a sepsis diagnostic), PAR Pharma (sells prepared bags of vasopressin). JAR reports having received an investigator-initiated grant from Grifols (entitled \u201cIs HBP a mechanism of albumin\u2019s efficacy in human septic shock?\u201d) that was provided to and administered by University of British Columbia.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}